The global IgA nephropathy market is set for substantial expansion over the next decade, with market size projected to nearly double from USD 46.82 billion in 2025 to USD 99.66 billion by 2035, registering a CAGR of 7.6%. Growth is primarily fueled by rising chronic kidney disease incidence, technological advancements in diagnostics, and the introduction of novel, disease-modifying therapies.
Market Dynamics and Key Drivers
Primary IgA nephropathy dominates the disease type segment, accounting for 81% of the market in 2025, driven by higher prevalence in APAC and Western countries and early detection via renal biopsies and proteinuria markers. Secondary IgA nephropathy, linked with systemic conditions such as liver cirrhosis and inflammatory bowel disease, is gradually gaining attention due to growing clinical research.
Explore trends before investing — request a sample report today!:- https://www.futuremarketinsights.com/reports/sample/rep-gb-16217
Hospitals remain the leading end-user segment, capturing 62.1% of the market in 2025, supported by specialized nephrology departments, integrated dialysis units, and access to emerging therapies like SGLT2 inhibitors and endothelin receptor antagonists. Their active role in clinical trials further strengthens market adoption.
A landmark development in IgA nephropathy treatment is Novartis AG’s Phase III APPLAUSE-IgAN trial, which demonstrated a 38.3% reduction in proteinuria over nine months with iptacopan (Fabhalta®), paving the way for FDA accelerated approval in 2024. This represents a transformative step as the first targeted oral therapy for progressive IgA nephropathy.
Biomarker Innovation Accelerates Early Diagnosis
Advancements in biomarker discovery, especially galactose-deficient IgA1 (Gd-IgA1), are revolutionizing early detection and disease management. Early identification allows patient stratification and targeted therapy with minimal systemic immunosuppression. Liquid biopsies and high-throughput mass spectrometry enhance assay accessibility, accuracy, and cost-effectiveness, expanding personalized treatment options.
Clinical Trials and Drug Preference Propel Market Growth
The proliferation of clinical trials for targeted therapies—complement pathway inhibitors, B-cell modulators, and biologics—accelerates drug approvals and enriches the treatment pipeline. Patients increasingly prefer pharmacological interventions over invasive dialysis, supported by improved efficacy, adherence, and quality of life.
Regional Market Insights
- USA: Leading North American growth with a CAGR of 6.2%, fueled by robust R&D infrastructure and pharmaceutical innovation.
- Germany: Western Europe’s market leader, growing at 4.4% CAGR, driven by research-intensive collaborations between academia and industry.
- India: Highest CAGR of 9.1% in South Asia & Pacific, driven by rising chronic kidney disease cases and increased demand for kidney transplant technologies.
- China & South Korea: Significant APAC growth, with 9% and 6% CAGR, respectively, reflecting rising patient awareness and adoption of novel therapies.
Click Here to Purchase the Report:- https://www.futuremarketinsights.com/checkout/16217
Market Segmentation Highlights
- Disease Type: Primary IgA nephropathy dominates with 81% share.
- End User: Hospitals lead at 62.1%, followed by specialty clinics and homecare segments showing steady growth.
- Therapy Mode: Oral small molecules and long-acting biologics gain traction over parenteral options due to convenience and adherence.
Competitive Landscape
Tier 1 companies, including Novartis, Sanofi, and AstraZeneca, control 58.9% of the market, leveraging strategic partnerships and extensive clinical trials. Mid-size Tier 2 players, such as Takeda and Pfizer, contribute 21.9%, focusing on agility and niche therapeutic areas. Tier 3 players like G Validus Pharmaceuticals and Organon cater to specialized segments, adding diversity and innovation.
Challenges and Restraints
Market growth is moderated by limited pipeline diversity, reflecting the complexity and heterogeneity of IgA nephropathy. This restricts therapeutic options, emphasizing the need for innovative approaches in immune modulation, complement system regulation, and fibrosis prevention.
Future Outlook
The global IgA nephropathy market is forecasted to maintain steady growth through 2035, supported by advanced diagnostics, expansion of targeted therapies, and increased patient preference for drug-based interventions over dialysis. APAC, Europe, the USA, and Saudi Arabia are expected to lead this growth trajectory, driven by rising disease prevalence and progressive healthcare infrastructure.
Why Choose FMI Empowering Decisions that Drive Real-World Outcomes:- https://www.futuremarketinsights.com/why-fmi
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analystsworldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: [email protected]
Website: https://www.futuremarketinsights.com
